Danny Rischin, MD, on Cemiplimab for Metastatic Squamous Cell Carcinoma

Posted: Tuesday, July 10, 2018

Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase II study findings on cemiplimab, a human monoclonal anti–PD-1 antibody, in patients with metastatic cutaneous squamous cell carcinoma.